This week, we’re discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with breast cancer may lead to increases in survival.

Coverage of stories discussed this week on ascopost.com:

Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer

FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates

To listen to more podcasts from ASCO, visit asco.org/podcasts.